All Stories

  1. Diagnostic value of CSF chromogranin A to discriminate between Alzheimer's disease and dementia with Lewy bodies

    Article • Neuropathology and Applied Neurobiology, February 2024, Wiley

    Dr Olivier BOUSIGES

  2. Involvement of ApoE4 in dementia with Lewy bodies in the prodromal and demented stages: evaluation of the Strasbourg cohort

    Article • GeroScience, August 2023, Springer Science + Business Media

    Dr Olivier BOUSIGES

  3. Epileptic Prodromal Alzheimer’s Disease Treated with Antiseizure Medications: Medium-Term Outcome of Seizures and Cognition

    Article • Journal of Alzheimer s Disease, August 2023, IOS Press

    Dr Olivier BOUSIGES, Dr Benjamin BC CRETIN

  4. Neural correlates of photophobia in prodromal and mild dementia with Lewy bodies

    Article • European Journal of Neurology, May 2023, Wiley

    Dr Olivier BOUSIGES

  5. Memory Outcome in Prodromal and Mild Dementia with Lewy Bodies and Alzheimer’s Disease: A Longitudinal Study

    Article • Journal of Alzheimer s Disease, May 2023, IOS Press

    Dr Olivier BOUSIGES

  6. Transient epileptic amnesia: a retrospective cohort study of 127 cases, including CSF amyloid and tau features

    Article • Journal of Neurology, January 2023, Springer Science + Business Media

    Dr Olivier BOUSIGES

  7. Neurofilaments contribution in clinic: state of the art

    Article • Frontiers in Aging Neuroscience, November 2022, Frontiers

    Dr Olivier BOUSIGES

  8. Les neurofilaments : un nouveau biomarqueur clé pour les cliniciens. Partie 1 : Intérêt des neurofilaments dans la prise en charge des maladies neurodégénératives

    Article • Annales de biologie clinique, September 2022, John Libbey Eurotext

    Dr Olivier BOUSIGES

  9. Les neurofilaments : un nouveau biomarqueur clé pour les cliniciens. Partie 2 : Neurofilaments, un intérêt au-delà des maladies neurodégénératives

    Article • Annales de biologie clinique, September 2022, John Libbey Eurotext

    Dr Olivier BOUSIGES

  10. Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort

    Article • Alzheimer s Research & Therapy, July 2022, Springer Science + Business Media

    Dr Olivier BOUSIGES

  11. Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer’s Disease

    Article • International Journal of Molecular Sciences, June 2022, MDPI AG

    Dr Olivier BOUSIGES

  12. Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects

    Article • Revue Neurologique, May 2022, Elsevier

    Dr Olivier BOUSIGES

  13. Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data

    Article • Alzheimer s Research & Therapy, January 2022, Springer Science + Business Media

    Dr Olivier BOUSIGES

  14. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

    Article • Alzheimer s & Dementia, December 2021, Wiley

    Mara D'Onofrio, Adelina Orellana, Dr Olivier BOUSIGES

  15. CSF in Epileptic Prodromal Alzheimer's Disease: No Diagnostic Contribution but a Pathophysiological One

    Article • Frontiers in Neurology, August 2021, Frontiers

    Dr Olivier BOUSIGES

  16. Association of cerebral microbleeds with cerebrospinal fluid Alzheimer‐biomarkers and clinical symptoms in early dementia with Lewy bodies

    Article • International Journal of Geriatric Psychiatry, December 2020, Wiley

    Dr Olivier BOUSIGES

  17. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer’s disease and dementia with Lewy bodies from the prodromal stage

    Article • Alzheimer s Research & Therapy, September 2020, Springer Science + Business Media

    Dr Olivier BOUSIGES

  18. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage

    Article • September 2020, Research Square

    Dr Olivier BOUSIGES

  19. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage

    Article • August 2020, Research Square

    Dr Olivier BOUSIGES

  20. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage

    Article • July 2020, Research Square

    Dr Olivier BOUSIGES

  21. Environmental exposure to phthalates and dementia with Lewy bodies: contribution of metabolomics

    Article • Journal of Neurology Neurosurgery & Psychiatry, July 2020, BMJ

    Dr Olivier BOUSIGES

  22. Total alpha-synuclein assay in cerebrospinal fluid is of interest in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage

    Article • June 2020, Research Square

    Dr Olivier BOUSIGES

  23. Total alpha-synuclein assay in the Cerebro-Spinal-Fluid is of interest in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage

    Article • March 2020, Research Square

    Dr Olivier BOUSIGES

  24. Dysregulation of histone acetylation pathways in hippocampus and frontal cortex of Alzheimer's disease patients

    Article • European Neuropsychopharmacology, February 2020, Elsevier

    Dr Olivier BOUSIGES

  25. The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies

    Article • NeuroImage Clinical, January 2020, Elsevier

    Dr Olivier BOUSIGES

  26. Diagnosis associated with Tau higher than 1200 pg/mL: Insights from the clinical and laboratory practice

    Article • Clinica Chimica Acta, August 2019, Elsevier

    Dr Olivier BOUSIGES

  27. CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies

    Article • Journal of Neurology Neurosurgery & Psychiatry, July 2019, BMJ

    Dr Olivier BOUSIGES

  28. GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study

    Article • Scientific Reports, May 2019, Springer Science + Business Media

    Dr Olivier BOUSIGES

  29. Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies

    Article • Clinica Chimica Acta, November 2018, Elsevier

    Dr Olivier BOUSIGES

  30. Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator

    Article • EMBO Molecular Medicine, October 2018, EMBO

    Dr Olivier BOUSIGES

  31. Diagnostic value of cerebrospinal fluid alpha-synuclein in dementia with Lewy body

    Article • Gériatrie et Psychologie Neuropsychiatrie du Viellissement, September 2018, John Libbey Eurotext

    Dr Olivier BOUSIGES

  32. Diagnostic value of Alzheimer's biomarkers in cerebrospinal fluid in dementia with Lewy body

    Article • Gériatrie et Psychologie Neuropsychiatrie du Viellissement, June 2018, John Libbey Eurotext

    Dr Olivier BOUSIGES

  33. Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers

    Article • Current Alzheimer Research, May 2018, Bentham Science Publishers

    olivier vercruysse, Dr Olivier BOUSIGES

  34. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage

    Article • Journal of Neurology Neurosurgery & Psychiatry, January 2018, BMJ

    Dr Olivier BOUSIGES

  35. Do we know how to diagnose epilepsy early in Alzheimer's disease?

    Article • Revue Neurologique, June 2017, Elsevier

    Dr Olivier BOUSIGES

  36. Les biomarqueurs du liquide cérébro-spinal dans la maladie d’Alzheimer : un outil de recherche utile dans la pratique clinique courante des consultations mémoire pour les cas complexes

    Article • La Revue de Médecine Interne, April 2017, Elsevier

    Dr Olivier BOUSIGES

  37. Epileptic Prodromal Alzheimer’s Disease, a Retrospective Study of 13 New Cases: Expanding the Spectrum of Alzheimer’s Disease to an Epileptic Variant?

    Article • Journal of Alzheimer s Disease, May 2016, IOS Press

    Dr Benjamin BC CRETIN, Dr Olivier BOUSIGES

  38. Late-Life Environmental Enrichment Induces Acetylation Events and Nuclear Factor  B-Dependent Regulations in the Hippocampus of Aged Rats Showing Improved Plasticity and Learning

    Article • Journal of Neuroscience, April 2016, Society for Neuroscience

    Dr Olivier BOUSIGES

  39. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer’s Disease and Dementia with Lewy Bodies

    Article • Journal of Alzheimer s Disease, April 2016, IOS Press

    Dr Olivier BOUSIGES

  40. Étude rétrospective observationnelle sur l’usage des biomarqueurs du liquide céphalorachidien de la maladie d’Alzheimer

    Article • NPG Neurologie - Psychiatrie - Gériatrie, February 2016, Elsevier

    Dr Olivier BOUSIGES

  41. Adenosine and Alzheimer’s Disease: A Possible Epigenetic Link

    Article • November 2015, Oxford University Press (OUP)

    Dr Olivier BOUSIGES

  42. Les biomarqueurs conventionnels de la maladie d’Alzheimer dans le LCR (Abeta42, Tau, Phospho-Tau) ne sont pas pathologiques chez les patients au stade prodromal d’une démence à Corps de Lewy

    Article • Revue Neurologique, April 2015, Elsevier

    Dr Olivier BOUSIGES

  43. Sarcoidosis Presenting As Late-Onset Dementia: Are Cerebrospinal Fluid Biomarkers Analyses Helpful?

    Article • Journal of the American Geriatrics Society, January 2015, Wiley

    Dr Olivier BOUSIGES

  44. CSF AD BIOMARKERS IN MEMORY CLINIC PATIENTS: THE EP.L.M.FR STUDY

    Article • Alzheimer s & Dementia, July 2014, Elsevier

    Dr Olivier BOUSIGES

  45. A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles

    Article • Alzheimer s Research & Therapy, January 2014, Springer Science + Business Media

    Dr Olivier BOUSIGES

  46. Acetyltransferases (HATs) as Targets for Neurological Therapeutics

    Article • Neurotherapeutics, September 2013, Springer Science + Business Media

    Dr Olivier BOUSIGES

  47. A Novel Activator of CBP/p300 Acetyltransferases Promotes Neurogenesis and Extends Memory Duration in Adult Mice

    Article • Journal of Neuroscience, June 2013, Society for Neuroscience

    Dr Olivier BOUSIGES

  48. Detection of Histone Acetylation Levels in the Dorsal Hippocampus Reveals Early Tagging on Specific Residues of H2B and H4 Histones in Response to Learning

    Article • PLoS ONE, March 2013, PLOS

    Dr Olivier BOUSIGES

  49. Spatial Memory Consolidation is Associated with Induction of Several Lysine-Acetyltransferase (Histone Acetyltransferase) Expression Levels and H2B/H4 Acetylation-Dependent Transcriptional Events in the Rat Hippocampus

    Article • Neuropsychopharmacology, September 2010, Nature

    Dr Olivier BOUSIGES

  50. Histone Deacetylase Inhibitors: Therapeutic Agents and Research Tools for Deciphering Motor Neuron Diseases

    Article • Current Medicinal Chemistry, June 2008, Bentham Science Publishers

    Dr Olivier BOUSIGES